INTREXON CORPORATION (NYSE:XON) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November27, 2017, the Board of Directors of Intrexon Corporation (“Intrexon”) promoted Lt. Gen. (Ret.) Thomas Bostick, Ph.D. to the position of Chief Operating Officer of Intrexon, replacing Andrew Last, Ph.D., who will not be remaining with Intrexon.
Lt. Gen. Bostick, age 61, joined Intrexon in September 2016 as Senior Vice President and Head of Intrexon’s Environment Sector. Lt. Gen. Bostick retired from the U.S. Army on July1, 2016 after 38 years of distinguished service. His last command was as the 53rd U.S. Army Chief of Engineers and the Commanding General of the U.S. Army Corps of Engineers (“USACE”), serving as the senior military officer overseeing and supervising most of the Nation’s civil works infrastructure and military construction, hundreds of environmental protection projects, as well as managing 34,000 civilian employees and military personnel in over 110 countries around the world. Before his command of USACE, which was from May 2012 to May 2016, Lt. Gen. Bostick served in a variety of command and staff assignments with the U.S. Army both in the U.S. and abroad including the Deputy Chief of Staff, G-1, Personnel, U.S. Army, Commanding General, U.S. Army Recruiting Command, Assistant Division Commander, 1st Cavalry Division, Executive Officer to the Chief of Engineers, Executive Officer to the Army Chief of Staff, and Deputy Director of Operations for the National Military Command Center, J-3, the Joint Staff in the Pentagon. Additionally, he was a special assistant to the Secretary of Veterans Affairs during his time as a White House Fellow. Lt. Gen. Bostick graduated with a Bachelor’s of Science degree from the U.S. Military Academy at West Point and later returned to the Academy to serve as an Assistant Professor of Mechanical Engineering. He holds Master’s degrees in Civil Engineering and Mechanical Engineering from Stanford University and a Doctorate in Systems Engineering from George Washington University.
In connection with his departure, to a severance agreement, Dr. Last will be entitled to a payment equivalent to sixteen weeks of his base pay, less applicable withholding amounts, and will be entitled to continue certain benefits, including health insurance, for a period of up to four months following his departure from Intrexon. The severance agreement also contains a general release by Dr.Last. The description of the severance agreement set forth herein does not purport to be complete and is qualified in its entirety by the full text of the severance agreement, a copy of which will be filed as an exhibit to Intrexon’s Form 10-K for the year ending December31, 2017.
On November27, 2017, Intrexon’s Board of Directors also promoted Nir Nimrodi to the position of Chief Business Officer of Intrexon, a newly created position. Prior to this promotion, Mr.Nimrodi served as Intrexon’s Senior Vice President, Corporate Development. Additional biographical information for Mr.Nimrodi is included on page 33 of Intrexon’s Definitive Proxy Statement for its 2017 Annual Meeting of Stockholders.
On November27, 2017, Intrexon issued a press release announcing the promotions of Lt. Gen. Bostick and Mr.Nimrodi and the promotion of Helen Sabzevari, PhD, to the position of President of Intrexon’s wholly-owned subsidiary, Precigen, Inc. A copy of that press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
|Item 5.02||Financial Statements and Exhibits.|
INTREXON CORP ExhibitEX-99.1 2 d475407dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Intrexon Announces Key Management Appointments GERMANTOWN,…To view the full exhibit click
About INTREXON CORPORATION (NYSE:XON)
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.